Reorganization of the Healthcare System During COVID-19 Pandemic: Impact on Management of Patients With Exocrine Pancreatic Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04406571

Acronym

CAPANCOVID-19

Enrollment

700

Registered

2020-05-28

Start date

2020-04-01

Completion date

2022-05-31

Last updated

2024-01-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Adenocarcinoma

Keywords

pancreatic adenocarcinoma, patient management, healthcare system reorganization, SARS-CoV-2

Brief summary

Pancreatic adenocarcinoma will be the 2nd cause of death by cancer in Europe in 2030. Pancreatic adenocarcinoma has poor prognosis with an all-stages combined 5-year survival rate below 8%. Since December 2019, a new coronavirus (Severe Acute Respiratory Syndrome Corona Virus 2, SARS-CoV-2) is responsible of COVID-19 infection with potentially severe respiratory syndrome or even multi-organ failure. An increased risk of severe COVID-19 infection in cancer patients is suggested in several Chinese series. Cancer care structures quickly reorganized to limit high-risk situations (diagnostic procedure, major surgery, cytotoxic poly-chemotherapy) and use alternatives such as on-hold chemotherapy. These reorganizations could be associated with a loss of chance for pancreatic adenocarcinoma.

Detailed description

The aim of this study is to study impact of reorganization of the healthcare system during COVID-19 pandemic on pancreatic adenocarcinoma patients management

Interventions

OTHERData record

Data record

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

: 1. aged 18 or over, 2. with pancreatic adenocarcinoma diagnosed by anatomopathological specimen or without biopsy but with suspicion of pancreatic adenocarcinoma in presence of imaging techniques or Ca19.9 level without evidence for neuroendocrine tumor, 3. assessed during multidisciplinary meeting in one participating center between 01/09/2019 and 31/10/2020, 4. accepting to participate to the study, 5. with or without SARS-CoV-2 infection.

Exclusion criteria

: 1. with neuroendocrine neoplasia 2. for whom histology showed non pancreatic 3. with cystadenoma or IPMN without invasive adenocarcinoma

Design outcomes

Primary

Measure	Time frame	Description
Pancreatic adenocarcinoma treatment	6 months	curative surgery (with or without chemotherapy), chemotherapy only or exclusive supportive care

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 19, 2026